Carvedilol

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 38, Issue , 2013, Pages 113-157

  Beattie, Kevin ^a   Phadke, Geeta ^a   Novakovic, Jasmina ^a  

^a Apotex Inc   (Canada)

Author keywords

ADME; Adrenoreceptor; Analysis; Carvedilol; Degradation; Impurities; Metabolism; Pharmacokinetics; Physical characteristics; Spectroscopy; Stability; Synthesis

Indexed keywords

CARVEDILOL;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMOLUMINESCENCE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG IMPURITY; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; MELTING POINT; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROFLUOROMETRY; TABLET; THERMOGRAVIMETRY; ULTRAVIOLET RADIATION; WETTABILITY; X RAY DIFFRACTION;

EID: 84878181415     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407691-4.00004-6     Document Type: Chapter

References (91)

1. The Merck Index (online), fourteenth ed., Whitehouse Station, NJ, Merck & Co. Inc. Search Term: Lamotrigine, accessed 2.11.2011. http://www.medicinescomplete.com/.
2. British Pharmacopoeia 2013, vol. 2, Carvedilol Monograph.
3. European Pharmacopoeia 7.0, vol. 2, Carvedilol Monograph.
4. Shewale B.D., et al. Effect of hydroxylpropyl-β-cyclodextrin on solubility of carvedilol. Ind. J. Pharm. Sci. 2008, 70:255-257.
5. A.V. Patil, et al., WO2008/083130 A2, 2008.
6. J. Desai, et al., WO2011/119477 A2, 2011.
7. Loftsson T., et al. Carvedilol: solubilization and cyclodextrin complexation: a technical note. AAPS Pharm. Sci. Tech. 2008, 9:425-430.
8. Menon S.K., et al. Evaluation and solubility improvement of carvedilol: PSC[n]arene inclusion complexes with acute oral toxicity studies. J. Incl. Phenom. Macrocycl. Chem. 2012, 73:295-303.
9. g drug. Powder Technol. 2006, 167:20-25.
10. ACD Labs, Release 11.00, Product Version 11.02, Build 25941, May 21, 2008.
11. Raut D.M., et al. Determination of traces of amorphous carvedilol content in carvedilol drug substance and drug product using modulated differential scanning colorimetry. Pharm. Lett. 2011, 3:1-12.
12. J. Hildesheim, et al., EP 1,655,285 A1, 2006.
13. P. Beyer, E. Reinholz, US 6,730,326 B2, 2004.
14. I. Kor, S. Wizel, US 2009/0163721 A1, 2009.
15. G.S. Ramanjaneyulu, et al., US 2009/0286991 A1, 2009.
16. J. Hildesheim, et al., US 2009/0326033 A1, 2009.
17. J. Aronhime, et al., AU 2007200344 A1, 2007.
18. J. Hildesheim, et al., US 2006/0030614 A1, 2006.
19. J. Hildesheim, et al., US 7,126,008 B2, 2006.
20. A.G. Bubendorf, et al., US 2006/0148878 A1, 2006.
21. A.G. Bubendorf, et al., US 2004/0198812 A1, 2004.
22. R. Zupet, et al., WO 2005/021504 A2, 2005.
23. I. Lifshitz, S. Wizel, US 2007/0043099 A1, 2007.
24. Yathirajan H.S., et al. A second polymorph of carvedilol. Acta Cryst. 2007, E63:o542-o544.
25. Diaz F., et al. 1-(9H-Carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}-propan-2-ol hemihydrates: a carvedilol solvatomorph. Acta Cryst. 2011, C67:o222-o225.
26. Almeida D.R.P., et al. Pharmacophore fragment-based prediction and gas-phase ab initio optimization of carvedilol conformations. J. Phys. Chem. A 2004, 108:6239-6247.
27. Almeida D.R.P., et al. Predicting the conformations of carvedilol based on its pharmacophore fragments: a gas phase and salvation ab initio and density functional study. J. Mol. Struct. (THEOCHEM) 2003, 666-667:537-545.
28. Almeida D.R.P., et al. Gas phase conformational basicity of carvedilol fragment B, 2(S)-1-(ethylammonium)propane-2-ol: an ab initio study on a protonophoretic of oxidative phosphorylation uncoupling. J. Mol. Struct. (THEOCHEM) 2003, 631:251-270.
29. Zoroddu M.A., et al. Metal-chelating properties of carvedilol: an antihypertensive drug with antioxidant activity. J. Coord. Chem. 2009, 62:3828-3836.
30. Zoroddu M.A., et al. Carvedilol, a β adrenoceptor blocker with chelating properties. A copper " superdimer" based on dimetal units. J. Inorg. Biochim. 2003, 95:315-320.
31. Lanzanova F.A., et al. LC and LC-MS evaluation of stress degradation behavior of carvedilol. J. Liq. Chromatogr. Rel. Technol. 2009, 32:526-543.
32. Rizwan M., et al. Study of the degradation kinetics of carvedilol by use of a validated stability-indicating LC method. Chromatographia 2009, 70:1283-1286.
33. United States Pharmacopoeia 35/National Formulary 30, Supplement 2, Carvedilol Monograph, 2012.
34. United States Pharmacopoeia 34/National Formulary 29, Carvedilol Tablets Monograph, 2012.
35. Radi A., Elmogy T. Differential pulse voltammetric determination of carvedilol in tablets dosage form using glassy carbon electrode. IL Farmaco 2005, 60:43-46.
36. Silva R.A., et al. Flow injection spectrofluorimetric determination of carvedilol mediated by micelles. Talanta 2008, 76:166-171.
37. Yilmaz B., Ekinci D. Voltammetric behavior of carvedilol in non-aqueous media and its analytical determination in pharmaceutical preparations. Rev. Anal. Chem. 2011, 30:187-193.
38. Pires C.K., et al. Chemiluminometric determination of carvedilol in a multi-pumping flow system. Talanta 2005, 68:239-244.
39. Xu L.X., et al. Study on fluorescence property of carvedilol and determination of carvedilol by fluorimetry. Spectrochim. Acta A 2005, 61:855-859.
40. Verma J.K., Syed H.A. Extractive spectrophotometric method for determination of carvedilol in tablets. Indian J. Pharm. Sci. 2007, 69:303-304.
41. Cardosa S.G., et al. Spectrophotmetric determination of carvedilol in pharmaceutical formulations through charge-transfer and ion-pair complexation reactions. Pharmazie 2001, 62:34-37.
42. Patel L.J., et al. RP-HPTLC and HPTLC methods for the estimation of carvedilol in bulk drug and pharmaceutical formulations. Indian J. Pharm. Sci. 2006, 68:790-792.
43. Stojanovic J., et al. Determination of carvedilol and its impurities in pharmaceuticals. Chromatographia 2005, 62:539-542.
44. Stojanovic J., et al. Monitoring of the photochemical stability of carvedilol and its degradation products by the RP-HPLC method. J. Serb. Chem. Soc. 2007, 72:37-44.
45. Basaveswara R.M.V., et al. New validated RP-HPLC method for the estimation of carvedilol in pharmaceutical formulation. Int. J. Pharm. Pharm. Sci. 2012, 4:353-358.
46. World Antidoping Program, , Accessed 23.10.2012. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2010_EN.pdf.
47. Talebpour Z., et al. Stir bar sorptive extraction and high performance liquid chromatographic determination of carvedilol in human serum using two different polymeric phases and an ionic liquid as desorption solvent. J. Chromatogr. A 2012, 1236:1-6.
48. Baranowska I., et al. Ultra HPLC method for the simultaneous analysis of drugs and flavonoids in human urine. J. Liq. Chromatogr. 2011, 34:421-435.
49. Baranowska I., et al. UHPLC method for the simultaneous determination of β-blockers, isoflavones and flavonoids in human urine. J. Chromatogr. Sci. 2011, 49:764-773.
50. Zakrzewski-Jakubiak M., et al. Enantioselective quantification of carvedilol in human plasma by HPLC in heavily medicated heart failure patients. J. Pharm. Biomed. Anal. 2010, 52:636-641.
51. Gomes N.A., et al. Application of a sensitive, rapid and validated LC-MS-MS method for the determination of carvedilol in human plasma. Chromatographia 2009, 69:19-25.
52. Medvedovici A., et al. Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes. J. Chromatogr. B 2007, 850:327-335.
53. Zarghi A., et al. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 2007, 44:250-253.
54. Rathod R., et al. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study. J. Chromatogr. B 2007, 857:219-223.
55. Li S., et al. Simultaneous determination of ten antiarrhythmic drugs and a metabolite in human plasma by liquid chromatograph-tandem mass spectrometry. J. Chromatogr. B 2007, 847:174-181.
56. Gannu R., et al. New RP-HPLC Method with UV-detection for the determination of carvedilol in human serum. J. Liq. Chromatogr. Rel. Technol. 2007, 30:1677-1685.
57. Won Jeong D., et al. Analysis of carvedilol in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. J. Pharm. Biomed. Anal. 2007, 44:547-552.
58. Saito M., et al. Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography. J. Chromatogr. B 2006, 843:73-77.
59. Myung S., Jo C.H. Gas chromatograph-mass spectrometric method for the determination of carvedilol and its metabolites in human urine. J. Chromatogr. B 2005, 822:70-77.
60. Carter do Carmo Borges N., et al. Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry application to bioequivalence study. J. Chromatogr. B 2005, 822:253-262.
61. Lamprecht G., Stoschitzky K. Determination of carvedilol in human plasma by high-performance liquid chromatography applying on-line deproteination and column switching. Chromatographia 2004, 59:551-554.
62. Yang E., et al. Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. J. Pharm. Biomed. Anal. 2004, 36:609-615.
63. Ptacek P., et al. Liquid chromatographic determination of carvedilol in human plasma. J. Chromatogr. B 2003, 789:405-410.
64. Machida M., et al. Measurement of carvedilol in plasma by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 2003, 798:187-191.
65. Lamprecht G., et al. Enantioselective analysis of (R)- and (S)-carvedilol in human plasma by high-performance liquid chromatography. Chromatographia 2002, 56:S25-S29.
66. Behn F., et al. HPLC quantification of carvedilol. Chromatographia 2001, 53:641-644.
67. Behn F., et al. Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. J. Chromatogr. B 2001, 755:111-117.
68. Gergov M., et al. Automated liquid chromatographic/tandem mass spectrometric method for screening β-blocking drugs in urine. J. Mass Spectrom. 2000, 35:912-918.
69. Keating G.M., Jarvis B. Carvedilol-a review of its use in chronic heart failure. Drugs 2003, 63:1697-1741.
70. Cubbedu L.X., et al. Clinical pharmacology of carvedilol in normal volunteers. Clin. Pharmacol. Ther. 1987, 41:31-44.
71. Möllendorf E.v., et al. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur. J. Clin. Pharamcol. 1987, 33:511-513.
72. Neugbauer G., et al. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 1987, 10:S85-S88.
73. Thi Phuong N., et al. Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch. Pharm. Res. 2004, 27:973-977.
74. Othman A.A., et al. Population pharmacokinetics of S(-)-Carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007, 9:E208-E218.
75. Gehr T.W.B., et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur. J. Clin. Pharmacol. 1999, 55:269-277.
76. Henderson L.S., et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am. J. Cardiol. 2006, 98:17L-26L.
77. Albers S., et al. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br. J. Clin. Pharmacol. 2007, 65:511-522.
78. Tenero D., et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J. Clin. Pharmacol. 2000, 40:844-853.
79. Packer M., et al. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am. J. Cardiol. 2006, 98:39L-45L.
80. Ruffolo R., et al. The pharmacology of carvedilol. Eur. J. Clin. Pharmacol. 1990, 38:S82-S88.
81. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 1994, 26:335-346.
82. Carlson W., Oberg K. Clinical pharmacology of carvedilol. J. Cardiovasc. Pharmacol. Ther. 1999, 4:205-218.
83. Neugbauer G., Neubert P. Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 1991, 16:257-260.
84. Oldham H.G., Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 1997, 25:970-977.
85. Neugbauer G., et al. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol. 1990, 38:S108-S111.
86. F. Wiedemann, et al., US 4,503,067, 1985.
87. A. Kumar, et al., EP 1 741 700 A1, 2007.
88. D.R. Shah, US 2008/0214833 A1, 2008.
89. S. Suri, T. Kashyap, WO 2008/038301 A1, 2008.
90. A. Modi, et al., WO 2009/115902 A1, 2009.
91. S.J. Kim, et al., US 2009/0176992 A1, 2009.